Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody

MW33 is a fully humanized IgG1κ monoclonal neutralizing antibody, and may be used for the prevention and treatment of coronavirus disease 2019 (COVID-19). We conducted a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 study to evaluate the safety, tolerability, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xianmin, Wang, Peipei, Xiong, Yanqing, Wu, Yijun, Lin, Xiaoyan, Lu, Song, Li, Ruowan, Zhao, Bei, Liu, Jing, Zeng, Shaoqing, Zeng, Liyan, Wu, Yan, Lu, Yan, Zhang, Jinchao, Liu, Datao, Wang, Shuhai, Lu, Hongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382006/
https://www.ncbi.nlm.nih.gov/pubmed/34346827
http://dx.doi.org/10.1080/22221751.2021.1960900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382006/
https://www.ncbi.nlm.nih.gov/pubmed/34346827
http://dx.doi.org/10.1080/22221751.2021.1960900

Ejemplares similares